Hemlibra®

HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

For indications, dosing and other information, please refer to the prescribing information.

Hemlibra® ‐ Genentech

Size:
30 mg, 1 mL Vial
NDC #:
50242-0920-01
Download:
PI
Size:
60 mg, 0.4 mL Vial
NDC #:
50242-0921-01
Download:
PI
Size:
105 mg, 0.7 mL Vial
NDC #:
50242-0922-01
Download:
PI
Size:
150 mg, 1 mL Vial
NDC #:
50242-0923-01
Download:
PI